Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.

[1]  J. Fargnoli,et al.  Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215) , 2008, Journal of medicinal chemistry.

[2]  J. Fargnoli,et al.  Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. , 2006, Journal of medicinal chemistry.

[3]  G. Soff,et al.  Update on angiogenesis inhibitors. , 2005, Current opinion in oncology.

[4]  J. Fargnoli,et al.  Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. , 2005, Journal of medicinal chemistry.

[5]  S. Barry,et al.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.

[6]  J. Fargnoli,et al.  Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[7]  Bart Landuyt,et al.  Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.

[8]  R. Ruel,et al.  Synthesis of functionalized 7-azaindoles via directed ortho-metalations ☆ , 2004 .

[9]  R. Ruel,et al.  Concise and efficient synthesis of 4-fluoro-1H-pyrrolo[2,3-b]pyridine. , 2003, Organic letters.

[10]  F. Rastinejad,et al.  Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. , 2003, Cancer research.

[11]  B. Ruggeri,et al.  A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clini , 2003, Journal of medicinal chemistry.

[12]  N. Pryer,et al.  Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. , 2003, Molecular cancer therapeutics.

[13]  P. Traxler.  Tyrosine kinases as targets in cancer therapy – successes and failures , 2003, Expert opinion on therapeutic targets.

[14]  L. Sepp-Lorenzino,et al.  Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development , 2002, Expert opinion on investigational drugs.

[15]  S. Wedge,et al.  Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. , 2002, Journal of medicinal chemistry.

[16]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[17]  G. Mcmahon,et al.  Receptor tyrosine kinases as targets for inhibition of angiogenesis , 1997 .